Efficiency and safety of oxcarbazepine in mood disorders: A naturalistic study exploring the interest of plasma dosages - 15/09/08
, Marie Tournier b, c, Tiphaine Droulout c, Adeline Grolleau b, Karine Titier b, Mathieu Molimard b, Helene Verdoux b, c
Corresponding author. Pôle de Psychiatrie adulte, Hôpital Charles Perrens, 121 rue de la Béchade, 33076 Bordeaux Cedex, France. Tel.: +33 5 56 56 34 50; fax: +33 5 56 56 35 46.Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 4 |
| Iconographies | 1 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Objective |
To investigate whether measurement of plasma levels can predict tolerance to oxcarbazepine (OXC).
Methods |
We reviewed medical records to identify all inpatients consecutively treated by OXC at the University Department of Psychiatry in Bordeaux. Adverse effects were rated before treatment onset, at day 3, then every week and at discharge or at discontinuation. Residual hydroxy-OXC concentrations were measured on blood samples at the same periods.
Results |
OXC was prescribed to 20 patients with bipolar (n=18) or schizoaffective bipolar-type disorder (n=2). Reported side effects were transient and occurred mostly at the beginning of the treatment. Three patients stopped OXC because of severe cutaneous side effects. Residual hydroxy-OXC plasma levels were similar in patients with or without occurrence of side effects at all times of assessment.
Conclusion |
Our data suggest that the occurrence of severe side-effects is relatively high with OXC. Measurement of plasma OXC levels does not appear to be of interest in clinical practice since plasma concentrations are not predictive of the occurrence of side effects.
Le texte complet de cet article est disponible en PDF.Keywords : Oxcarbazepine, Bipolar disorder, Anticonvulsants
Plan
Vol 23 - N° 6
P. 409-412 - septembre 2008 Retour au numéro
Article précédent
- Impact of the WHO depression guideline on patient care by psychiatrists: A randomized controlled trial
- Michel Linden, Anja Westram, Lutz G. Schmidt, Clemenz Haag
- Altered glial cell line-derived neurotrophic factor (GDNF) concentrations in the brain of patients with depressive disorder: A comparative post-mortem study
- Tanja M. Michel, Sophia Frangou, Sibylle Camara, Dorothea Thiemeyer, Julia Jecel, Thomas Tatschner, Robert Zoechling, Edna Grünblatt
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?